EMA Proposes Decision Tree Approach to Environmental Risk Assessments

Drug Industry Daily
A A
The EMA’s Committee for Medicinal Products for Human Use released draft guideline on environmental risk assessments for human drugs — including decision trees to help sponsors decide if they need a Phase I, Phase II or customized risk assessment.

To View This Article:

Login

Subscribe To Drug Industry Daily